Lack of combination effects of soy isoflavones and taxane chemotherapy of castration‐resistant prostate cancer. Issue 2 (21st October 2018)

• Record Type: Journal Article
• Authors: Eskra, Jillian N.; Schlicht, Michael J.; Bosland, Maarten C.
• Is Part Of: Prostate. Volume 79:Issue 2(2019)
• Page Start: 223
• Page End: 233
• Publication Date: 2018-10-21
• Subjects: castration‐resistant -- genistein -- prostate cancer -- soy isoflavones -- taxane chemotherapy; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23727
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract : Background: Patients with cancer, including prostate cancer, often use dietary supplements, such as soy or isoflavones, before, during, or after therapy. There is little information about possible interactions between supplements and cancer chemotherapy. There are some reports suggesting enhancement by genistein of taxane chemotherapy for castrate‐resistant prostate cancer (CRPC). Methods: We investigated whether physiologically attainable concentrations of soy isoflavones (≤10 μM) interact with taxanes on growth inhibition of CRPC cells in vitro and in vivo in nude mice exposed via the diet, on microtubule disassembly in vitro, and on P‐glycoprotein‐mediated drug efflux in 22Rv1 cells and CYP3A4 activity in microsomes. Results: Genistein, daidzein, and equol did not affect growth of VCaP, 22Rv1, C4‐2, and PC‐3 CRPC cells or growth inhibition of these cells by docetaxel and cabazitaxel. These isoflavones did not inhibit microtubule disassembly in vitro or inhibit the microtubule effects of taxanes and genistein did not bind substantially to microtubules. Genistein considerably inhibited P‐glycoprotein‐mediated drug efflux in 22Rv1 cells and CYP3A4 activity in microsomes. However, dietary supplementation with genistein at 250 and 500 ppm did not affect the tumor growth inhibiting effect of docetaxel on 22Rv1 cells xenografted in nude mice. Conclusions: Our results with relevant cell models and clinically achievable concentrations of soy isoflavones do not support the notion that genistein or other soy isoflavones can enhance the effects of taxane chemotherapy in CRPC cell and xenograft models. Yet, the inhibitory effects of genistein on drug efflux in 22Rv1 cells and on microsomal CYP3A4 activity raise the possibility that genistein can affect taxane effects on CRPC cells in other circumstances than those we studied, which merits further research.